Zenith Drugs
Zenith Drugs (ZENITHDRUG) share price was ₹37.00 at the 28 Oct 2026 close; market capitalisation ₹63.45 Cr; sector Healthcare. The share price fell 42.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue was ₹93 Cr, against ₹66 Cr a year earlier and net profit was ₹2 Cr, against ₹1 Cr a year earlier (compared with Mar 2025). Promoters held 69.98% of Zenith Drugs in Mar 2026, unchanged from Sep 2025. Its Tapetide Score is 57/100 (Good) as of 28 Oct 2026.
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 28 Oct 2026, 13:12 IST · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,763.60 | 34.99 | 4,23,147 Cr | 5.06 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,678.50 | 87.84 | 2,56,934 Cr | 15.33 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,588.30 | 72.03 | 1,74,524 Cr | 9.50 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,195.10 | 108.45 | 1,18,604 Cr | 22.38 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,183.20 | 26.33 | 1,18,025 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,338.80 | 34.67 | 1,11,747 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.20 | 32.71 | 1,10,289 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Zenith Drugs (this company) | ₹37.00 | — | 63 Cr | 0.87 | 1.33% | 15.48% | 23.19% | — | — |
| Median 8 companies | ₹1,564.40 | 34.99 | 1,18,314 Cr | 4.71 | 0.72% | 14.56% | 18.45% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 84/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.94 times its book value
Weaknesses
5- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 12.5% over last 3 years.
- Earnings include an other income of Rs.4.89 Cr.
- Company has high debtors of 157 days.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 6% · Mar 2026
Quarterly Results
| Particulars | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 69 | 62 | 68 | 66 | 78 | 93 |
| Expenses | 58 | 56 | 61 | 59 | 72 | 87 |
| Operating Profit | 11 | 6 | 7 | 7 | 6 | 6 |
| OPM % | 16% | 9% | 10% | 10% | 8% | 6% |
| Other Income | -1 | 2 | 1 | 1 | 2 | 3 |
| Interest | 1 | 2 | 1 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 2 | 3 | 3 |
| PBT | 8 | 6 | 6 | 4 | 2 | 3 |
| Tax % | 25% | 32% | 0% | 59% | 0% | 48% |
| Net Profit | 6 | 4 | 6 | 1 | 2 | 2 |
| EPS (₹) | 4.75 | 2.24 | 3.34 | 0.84 | 1.36 | 0.94 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 78 | 72 | 92 | 115 | 131 | 132 | 171 |
| Expenses | 71 | 64 | 85 | 105 | 114 | 119 | 158 |
| Operating Profit | 7 | 7 | 7 | 9 | 17 | 14 | 12 |
| OPM % | 9% | 10% | 8% | 8% | 13% | 10% | 7% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| Interest | 1 | 1 | 2 | 2 | 3 | 4 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 3 | 6 |
| PBT | 5 | 5 | 4 | 7 | 13 | 9 | 5 |
| Tax % | 30% | 33% | 27% | 27% | 28% | 23% | 27% |
| Net Profit | 3 | 3 | 3 | 5 | 10 | 7 | 4 |
| EPS (₹) | — | — | — | — | 5.56 | 4.18 | 2.3 |
| Div. Payout % | 0% | 0% | 0% | 0% | 9% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.4 | 0.4 | 0.4 | 0.4 | 17 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 52 | 56 |
| Borrowings | 12 | 15 | 17 | 25 | 24 | 49 | 55 |
| Other Liabilities | 25 | 21 | 37 | 54 | 48 | 44 | 59 |
| Total Liabilities | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
| Fixed Assets | 6 | 9 | 10 | 11 | 11 | 40 | 37 |
| CWIP | 3 | 0 | 0 | 0 | 4 | 3 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 35 | 37 | 56 | 86 | 119 | 118 | 136 |
| Total Assets | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 3 | -1 | 5 | -4 | -16 | -5 | 9 |
| Investing | -5 | -2 | -3 | -2 | -5 | -31 | -14 |
| Financing | 1 | 3 | -1 | 6 | 30 | 28 | 5 |
| Net Cash Flow | 0 | 0 | 1 | 0 | 9 | -8 | 0 |
| Free Cash Flow | -1 | -2 | 2 | -6 | -21 | -37 | -5 |
| CFO/OP | 71 | 7 | 88 | -27 | -70 | -25 | 86 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | 157 | 188 | 167 | 157 |
| Inventory Days | 29 | 52 | 61 | — | 249 | 277 | 257 |
| Days Payable | 155 | 155 | 173 | — | 412 | 281 | 337 |
| Cash Conversion Cycle | -7 | 17 | 16 | 157 | 25 | 163 | 77 |
| Working Capital Days | 14 | 24 | 21 | 39 | 111 | 91 | 74 |
| ROCE % | — | 28% | 24% | 25% | 28% | 13% | 9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Zenith Drugs insights
64 extracted metrics + investor summaries across FY20–FY26.
Documents
Frequently Asked Questions about Zenith Drugs
What does Zenith Drugs Ltd do?
Where is Zenith Drugs Ltd (ZENITHDRUG) listed?
Which sector does Zenith Drugs Ltd belong to?
What is the market capitalisation of Zenith Drugs Ltd?
What is the 52-week high and low of Zenith Drugs Ltd?
Does Zenith Drugs Ltd pay dividends?
What is the Return on Equity (ROE) of Zenith Drugs Ltd?
Company Information
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing and trading of medicines[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZENITHDRUG.md for Zenith Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.